FDA Labeling Changes for Oral Semaglutide: Cardiovascular Risk Insights

Key Takeaways

• Main news: The U.S. Food and Drug Administration (FDA) expanded the labeling for oral semaglutide (Rybelsus) on October 17, 2025, to include cardiovascular risk reduction in adults with Type 2 Diabetes at high cardiovascular risk.
• Clinical impact: The SOUL trial demonstrated a 14% relative risk reduction in major adverse cardiovascular events (MACE) with oral semaglutide compared to placebo.
• Market implications: This expanded indication broadens the eligible patient population for oral semaglutide, strengthening its position in the competitive Cardiovascular Disease and diabetes market.
• Next steps: The expanded label may influence prescribing practices among healthcare professionals and shape future clinical guidelines.

The semaglutide (Rybelsus) label was updated by the FDA on October 17, 2025, to include data on the FDA GLP-1 receptor agonist approval for reducing major adverse cardiovascular events (MACE). This decision follows the SOUL trial, which demonstrated a significant reduction in cardiovascular risk in adults with type 2 diabetes at high cardiovascular risk, even those without prior cardiovascular events. Why it matters: This expanded indication offers a new treatment option for a broader population of patients with type 2 diabetes, potentially improving cardiovascular outcomes.

Drug Overview

Oral semaglutide (Rybelsus) is a glucagon-like peptide-1 (GLP-1) receptor agonist. As a GLP-1 receptor agonist, semaglutide improves glycemic control. The FDA has approved oral semaglutide (Rybelsus 7 mg and 14 mg tablets) for reducing major adverse cardiovascular events in adults with type 2 diabetes at high cardiovascular risk, including patients without prior cardiovascular events.

Clinical Insights

The expanded FDA labeling was based on the Phase III SOUL trial (NCT03914326). This trial assessed the efficacy and safety of oral semaglutide in reducing major adverse cardiovascular events (MACE) in adults with type 2 diabetes at high cardiovascular risk. The primary endpoint was MACE. The SOUL trial demonstrated a 14% relative risk reduction in MACE with oral semaglutide compared to placebo.

Regulatory Context

On October 17, 2025, the FDA approved the expanded labeling for oral semaglutide (Rybelsus) based on the SOUL trial results. This approval is a full indication expansion.

Market Impact

The expanded label increases the eligible patient pool and strengthens oral semaglutide’s position among GLP-1 receptor agonists competing in the diabetes market. Oral semaglutide offers a convenient oral formulation with proven cardiovascular risk reduction, differentiating it from injectable GLP-1 receptor agonists. This positions it favorably compared with other drugs in its class, such as FDA liraglutide approval and FDA dulaglutide approval. What to watch next: The expanded label is expected to influence prescribing practices among healthcare professionals, potentially increasing the market share of oral semaglutide in the treatment of type 2 diabetes with cardiovascular risk.

Future Outlook

Potential for further FDA labeling expansions or new indications based on ongoing cardiovascular outcomes research. This may impact clinical guidelines for managing type 2 diabetes with cardiovascular risk. Considerations for patient management, including risk stratification and treatment personalization.

Frequently Asked Questions

References

References

1. U.S. Food and Drug Administration. FDA approval. Accessed 2026-04-26.